Clinical Effectiveness of Enteric Coated(E.C.) Anise-oil on Irritable Bowel Syndrome (IBS-Anise)
Randomised Clinical Trial: Enteric-coated Anise-oil Capsules vs. Placebo & Active Controlled in Irritable Bowel Syndrome - A 4 Week Double-blind Study With 2 Weeks Follow-up
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Fars
-
Shiraz, Fars, Iran, Islamic Republic of
- Dr. Kamran Bagheri Lankarani
-
Shiraz, Fars, Iran, Islamic Republic of
- Dr. Maryam Mosaffa-Jahromi
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meeting the Rome III Modular Questionnaire
- Patients with 50 years were required to have a colonoscopy performed within the previous 5 years
- Patients under the age of 50 years were required to have a sigmoidoscopy performed
Exclusion Criteria:
- Unable or unwilling patients to use an acceptable method of birth control
- Pregnant or nursing females
- Previous gastrointestinal or abdominal surgery (except for common causes unrelated to IBS)
- Organic disorder of the large or small bowel (e.g. ulcerative colitis, Crohn's disease)
- Mechanical obstruction
- Unexplained significant weight loss or rectal bleeding
- Diagnosis of any medical condition associated with constipation (other than IBS)
- Cancer
- Abnormal laboratory tests
- Abuse of alcohol or drugs
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Anise-oil EC
Intervention Group: Anise-oil EC Capsule,One Cap(187mg)/day for 4 weeks.
Patients will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
|
Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
Other Names:
|
|
Placebo Comparator: Placebo
Placebo Group: One Placebo Capsule/Day for 4 Weeks.
Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
|
One Placebo Capsule/Day for 4 Weeks
Other Names:
|
|
Active Comparator: Colpermin®
Colpermin® Group: One Colpermin® Capsule/Day for 4 Weeks.
Patients Will be Followed at Baseline, 4 and 6 Weeks after Starting Intervention.
|
Colpermin® Capsule/Day for 4 Weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of Quality of Life (QOL), pain, flatulence, diarrhea, constipation, reflux, headache and tiredness
Time Frame: Baseline
|
(IBS-QOL) questionnaire and 10-point visual scale ranging
|
Baseline
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composite of Change in Quality of Life (QOL), pain, flatulence, diarrhea, constipation, reflux, headache and tiredness at end of treatment
Time Frame: 4 weeks after start treatment
|
(IBS-QOL) questionnaire and 10-point visual scale ranging
|
4 weeks after start treatment
|
|
Composite of Change in Quality of Life (QOL), pain, flatulence, diarrhea, constipation, reflux, headache and tiredness at end of treatment
Time Frame: End of Follow Up(6 weeks after staring intervention)
|
(IBS-QOL) questionnaire and 10-point visual scale ranging
|
End of Follow Up(6 weeks after staring intervention)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Maryam Mosaffa-Jahromi, PhDc, Department of Traditional Pharmacy, School of Pharmacy and Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- E.C. Anise-oil on IBS
- Dr.Mosaffa (Registry Identifier: Dr.Mosaffa)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.